摘要
目的观察孟鲁司特治疗慢性阻塞性肺疾病(COPD)急性加重期的疗效方法将90例处于急性加重期的COPD患者随机分为对照组和治疗组,每组45例,对照组给予常规治疗,治疗组在此基础上加用孟鲁司特,疗程为2周,比较2组治疗前后血气分析与肺功能。结果与对照组治疗后比较,治疗组治疗后PaO2、FEV1/FVC、FEV1/预计值明显上升,PaCO2降低,差异均有统计学意义(P<0.05)。结论孟鲁司特治疗COPD急性加重期疗效较好,可明显改善患者的呼吸功能。
Objective To observe the curative efficacy of montelukast on chronic obstructive pulmonary disease （COPD） with acute exacerbation stage. Methods Ninety patients with acute exacerbation stage of COPD were randomly divided into control group and therapeutic group. Each group included 45 cases. Control group received conventional treatment, whereas therapeutic group was given conventional treatment plus montelukast. After 2 weeks of treatment, blood gas analysis and pulmonary function before and after treatment were compared between control group and therapeutic group. Results PaO2, FEV1/FVC and FEV1/predictive value were significantly higher in therapeutic group after treatment than those in control group （P0.05）.However, PaCO2 was decreased in therapeutic group after treatment as compared with control group （P0.05）.Conclusion Montelukast has a better clinical effectiveness to treat COPD with acute exacerbation stage, and it can markedly alleviate respiratory function of patients.
出处
《中国实用医药》
2013年第16期38-39,共2页
China Practical Medicine
关键词
孟鲁司特
慢性阻塞性肺疾病
血气分析
肺功能
Montelukast
Chronic obstructive pulmonary disease
Blood gas analysis
Pulmonary function
